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Congenital cytomegalovirus (cCMV) infection is a common and yet underappreciated cause 
of hearing loss and neurodevelopment disability in US children.1 Any opportunity to achieve 
early detection of cCMV and provide interventions warrants careful consideration.
Diener et al2 in this issue document the experience with targeted screening for cCMV in 
Utah among infants who do not pass newborn hearing screening (NBHS). Since July 2013, 
Utah has required referral for testing for cytomegalovirus (CMV) within 21 days of birth for 
newborns who do not pass NBHS and follow-up outpatient screening.3 Most notably, the 
introduction of targeted screening for cCMV, along with state-funded public education about 
cCMV, was associated with an increase from 56% to 77% in timely diagnostic audiology 
follow-up (<90 days) of infants who did not pass NBHS.2 That is important because timely 
diagnosis and early intervention for sensorineural hearing loss (SNHL) improves long-term 
language outcomes.4
That said, Utah’s experience with targeted screening (ie, targeted testing based on a marker 
of suspected infection5) raises as many questions as it answers. Targeted screening for 
cCMV resulted in the identification of 14 children with confirmed cCMV in 24 months, but 
during the same period an estimated 400 to 700 infants in Utah were born with cCMV, based 
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on 103 868 births during that time.6 If it is indeed urgent to detect infants with cCMV, why 
not screen all newborns? How do the potential benefits of each approach compare with the 
costs and burden of testing and follow-up?
Diener et al2 mention the main benefit of targeted screening as the focused surveillance and 
monitoring of children with asymptomatic cCMV infections at risk for late-onset and 
progressive SNHL. However, all infants with cCMV are at risk for SNHL, most of whom are 
not detected by targeted screening. Furthermore, it is unclear how audiologic monitoring 
should be done. Although monitoring of children with cCMV for SNHL is endorsed by the 
Joint Committee on Infant Hearing (2007),7 it is not stated how often, for how long, or by 
whom testing should occur.
The other benefit of targeted screening mentioned by Diener et al2 is the opportunity to 
diagnose infants with symptomatic cCMV infections, although how this would occur was 
not explained, and mandated testing in Utah did not detect such infants. Symptomatic cCMV 
with central nervous system involvement is medically actionable, with treatment with 
valganciclovir recommended beginning in the first month of life.8 Two clinical trials of 
antiviral treatment in such infants demonstrated significantly better hearing and 
neurodevelopmental outcomes despite the risk of neutropenia.9, 10 Universal screening of 
newborns for cCMV has the potential of increasing detection of symptomatic infections, but 
targeted screening falls short. In Utah, 13 other infants were clinically diagnosed in 2 years,2 
compared with an expected 40 to 100 symptomatic cases.11
A controversial aspect of targeted screening in Utah is that antiviral treatment is offered to 
asymptomatic infants with cCMV12 despite a lack of evidence of benefit and safety in that 
population. That practice is not endorsed by professional societies.8 Trials of valganciclovir 
in infants with asymptomatic cCMV are under way, but it will be several years before results 
are known.5
Other questions include how infants should be tested for CMV, how much it costs, and who 
pays for it. Specimens should be collected within 21 days to test for CMV, which is not easy 
to do in targeted screening programs if, as in Utah, outpatient NBHS is conducted at ~14 
days. The cost of targeted screening in Utah has been reported to be $66 per specimen,12 but 
it is unclear what that cost covers. A recent hypothetical cost-effectiveness analysis posited 
that testing for CMV by using saliva specimens for either targeted or universal screening 
would cost between $10 and $50 per specimen.13 However, the analysis assumed no added 
cost to public health systems, which may be unrealistic.
Universal screening for cCMV would be a substantial undertaking and faces multiple 
challenges. No prospective population-based pilot screening studies have been conducted to 
demonstrate feasibility and affordability within a public health context. Use of dried blood 
spot specimens would be ideal, but sensitivity may be problematic14, 15; assays using saliva 
have greater analytic sensitivity but require a new testing infrastructure with associated 
costs.16 One study designed to assess high-throughput assays by using both saliva and dried 
blood spots in screening unselected newborns is under way in Minnesota. Universal newborn 
cCMV screening would also require standardized protocols and data systems for monitoring 
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large numbers of children with cCMV, along with assessment of workforce capacity. Finally, 
consensus is needed on which infants with cCMV are appropriate candidates for medical 
treatment.
The experience of Utah as the first state to implement targeted screening for cCMV is 
instructive and will contribute to discussions of appropriate ways to achieve early detection 
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